TY - JOUR
T1 - A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer
AU - Shitara, Kohei
AU - Sawaki, Akira
AU - Matsuo, Keitaro
AU - Kondo, Chihiro
AU - Takahari, Daisuke
AU - Ura, Takashi
AU - Tajika, Masahiro
AU - Niwa, Yasumasa
AU - Muro, Kei
PY - 2013/6
Y1 - 2013/6
N2 - Background: Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. Methods: We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. Results: From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand-foot syndrome was more common in the XP group, no patients experienced grade 3 or more. Conclusions: Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC.
AB - Background: Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. Methods: We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. Results: From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand-foot syndrome was more common in the XP group, no patients experienced grade 3 or more. Conclusions: Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC.
UR - http://www.scopus.com/inward/record.url?scp=84879422070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879422070&partnerID=8YFLogxK
U2 - 10.1007/s10147-012-0416-6
DO - 10.1007/s10147-012-0416-6
M3 - Article
C2 - 22552360
AN - SCOPUS:84879422070
SN - 1341-9625
VL - 18
SP - 539
EP - 546
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 3
ER -
